In March 2006, Bayer AG's €16.3 billion ($19.6 billion) cash offer for Schering trumped compatriot Merck KGAA's unsolicited €14.6 billion takeover bid for the specialist pharma marketer. The offers to acquire Schering put a spotlight on Europe's mid-sized players, most of which are either on the acquisition trail or putting up For Sale signs in front of corporate headquarters.
Schering AG CEO Hubertus Erlen, PhD, has long espoused the value of franchise building and specialist marketing. (See "Schering: Addressing the Specialist Challenge," IN VIVO, November 2004 Also see "Schering: Addressing the Specialist Challenge" - In Vivo, 1 November, 2004..) Now he can finally put a number on that value: about $20 billion.
In March 2006, Bayer AG 's €16.3 billion ($19.6 billion) cash offer for Schering trumped compatriot Merck KGAA ...
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
Many assets do not meet their pre-launch predictions, either exceeding or falling short of their forecast sales. In this article, In Vivo highlights several historic examples and the factors that influenced their unexpected performance.
